Light Mode
$6.59 ↑ +0.00 (+0.00%) Trading Up from the previous close of $6.59, and at the day’s high of $6.59
+1.53 (+30.24%) / 6M
Momentum, market sentiment, and recent alerts
BOLT reads neutral: price sits above both the 20- and 200-day averages, the 12-month move is +14.4%.
Earnings, valuation, and balance sheet
Company profile and competitor comparison
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Its pipeline includes BDC-1001, a HER2-targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. The company was founded by Edgar G. Engleman on January 22, 2015 and is headquartered in Redwood City, CA.
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.